Micro Assays for HemATology Malignancies Antibody Treatment

Inclusion criteria

• Male or Female over 18 years of age
• Patient with a hematological malignancy likely to benefit from immunotherapy (in any form; at the discretion of the referring physician)
• Before the start of 1st-line treatment, successive lines or before autograft (chemotherapy-free for at least 4 weeks in these cases).
• Patient has received information about the study and has not expressed opposition.
• Patient who is a beneficiary or entitled beneficiary of a social security scheme

Exclusion criteria

• Person in a period of exclusion from another research protocol at the time the non-opposition is signed.
• Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code, i.e. :

• Persons deprived of their liberty by judicial or administrative decision
• Persons subject to psychiatric monitoring under articles L3112-1 and L3113-1 who are not covered by the provisions of article L1121-8
• Minors
• Adults under legal protection or unable to express their consent.
• A person who cannot read and understand the French language well enough to be able to consent to take part in research.